175 related articles for article (PubMed ID: 23627578)
1. Impact of clinical pharmacists' recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice.
Bundeff AW; Zaiken K
J Manag Care Pharm; 2013 May; 19(4):325-33. PubMed ID: 23627578
[TBL] [Abstract][Full Text] [Related]
2. Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists' effect on prescribing practice at a tertiary hospital.
Luo H; Fan Q; Xiao S; Chen K
BMC Health Serv Res; 2018 Jul; 18(1):537. PubMed ID: 29996830
[TBL] [Abstract][Full Text] [Related]
3. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program.
Jacobson Vann JC; Christofferson S; Humble CG; Wegner SE; Feaganes JR; Trygstad TK
J Manag Care Pharm; 2010 May; 16(4):250-63. PubMed ID: 20433216
[TBL] [Abstract][Full Text] [Related]
4. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
5. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
[TBL] [Abstract][Full Text] [Related]
6. Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic.
Odenthal DR; Philbrick AM; Harris IM
J Am Pharm Assoc (2003); 2020; 60(1):100-104. PubMed ID: 31601478
[TBL] [Abstract][Full Text] [Related]
7. Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program.
DeName B; Divine H; Nicholas A; Steinke DT; Johnson CL
J Am Pharm Assoc (2003); 2008; 48(6):731-6. PubMed ID: 19019801
[TBL] [Abstract][Full Text] [Related]
8. Awareness, attitude and behavior regarding proton pump inhibitor among medical staff in the Southwest of China.
Luo H; Fan Q; Bian T; Li X; Chen K; Zhang Q; Wei Y; Xiao Y; Li Y
BMC Health Serv Res; 2019 Nov; 19(1):880. PubMed ID: 31752835
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with the initiation of proton pump inhibitors in corticosteroid users.
Munson JC; Wahl PM; Daniel G; Kimmel SE; Hennessy S
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):366-74. PubMed ID: 22278844
[TBL] [Abstract][Full Text] [Related]
10. Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults.
Michal J; Henry T; Street C
Am J Health Syst Pharm; 2016 Sep; 73(17 Suppl 4):S126-32. PubMed ID: 27543598
[TBL] [Abstract][Full Text] [Related]
11. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.
Solem C; Mody R; Stephens J; Macahilig C; Gao X
J Am Pharm Assoc (2003); 2014; 54(2):144-53. PubMed ID: 24632930
[TBL] [Abstract][Full Text] [Related]
12. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.
Targownik LE; Fisher DA; Saini SD
Gastroenterology; 2022 Apr; 162(4):1334-1342. PubMed ID: 35183361
[TBL] [Abstract][Full Text] [Related]
13. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system.
Altavela JL; Jones MK; Ritter M
J Manag Care Pharm; 2008; 14(9):831-43. PubMed ID: 19006440
[TBL] [Abstract][Full Text] [Related]
14. Proton-pump inhibitor utilization associated with the change to nonpreferred formulary status for esomeprazole in the TRICARE formulary.
Linton A; Bacon T; Peterson M
J Manag Care Pharm; 2009; 15(1):42-54. PubMed ID: 19125549
[TBL] [Abstract][Full Text] [Related]
15. Do recent reports about the adverse effects of proton pump inhibitors change providers' prescription practice?
Al-Qaisi MT; Kahn A; Crowell MD; Burdick GE; Vela MF; Ramirez FC
Dis Esophagus; 2018 Dec; 31(12):. PubMed ID: 29873678
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the prescription of proton pump inhibitors in persons aged 75years and older in a geriatric acute-care unit].
Dipanda M; Pioro L; Buttard M; d'Athis P; Asgassou S; Putot S; Deïdda M; Laborde C; Putot A; Manckoundia P
Therapie; 2017 Dec; 72(6):669-675. PubMed ID: 28939010
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy.
Lodato F; Poluzzi E; Raschi E; Piccinni C; Koci A; Olivelli V; Napoli C; Corvalli G; Nalon E; De Ponti F; Zoli M
Eur J Intern Med; 2016 May; 30():31-36. PubMed ID: 26926561
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US.
Rane PP; Guha S; Chatterjee S; Aparasu RR
Res Social Adm Pharm; 2017; 13(2):358-363. PubMed ID: 27033427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
